Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Income Statement
Earnings Waterfall
Clarus Therapeutics Holdings Inc
Revenue
|
16.9m
USD
|
Cost of Revenue
|
-3.6m
USD
|
Gross Profit
|
13.3m
USD
|
Operating Expenses
|
-53.2m
USD
|
Operating Income
|
-39.9m
USD
|
Other Expenses
|
7.3m
USD
|
Net Income
|
-32.6m
USD
|
Income Statement
Clarus Therapeutics Holdings Inc
Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | ||
---|---|---|---|---|---|---|---|
Revenue | |||||||
Revenue |
7
N/A
|
12
+73%
|
14
+17%
|
16
+15%
|
18
+10%
|
17
-6%
|
|
Gross Profit | |||||||
Cost of Revenue |
(1)
|
(2)
|
(2)
|
(3)
|
(3)
|
(4)
|
|
Gross Profit |
6
N/A
|
10
+70%
|
12
+18%
|
13
+10%
|
15
+10%
|
13
-9%
|
|
Operating Income | |||||||
Operating Expenses |
(36)
|
(64)
|
(63)
|
(64)
|
(65)
|
(53)
|
|
Selling, General & Administrative |
(33)
|
(59)
|
(59)
|
(59)
|
(63)
|
(49)
|
|
Research & Development |
(3)
|
(4)
|
(4)
|
(5)
|
(5)
|
(4)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
3
|
0
|
|
Operating Income |
(30)
N/A
|
(54)
-80%
|
(51)
+5%
|
(51)
+2%
|
(51)
-1%
|
(40)
+21%
|
|
Pre-Tax Income | |||||||
Interest Income Expense |
(14)
|
(23)
|
(23)
|
(21)
|
(18)
|
(10)
|
|
Non-Reccuring Items |
0
|
0
|
3
|
3
|
0
|
4
|
|
Total Other Income |
34
|
34
|
21
|
13
|
13
|
14
|
|
Pre-Tax Income |
(10)
N/A
|
(43)
-344%
|
(51)
-19%
|
(56)
-9%
|
(55)
+1%
|
(33)
+41%
|
|
Net Income | |||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(10)
|
(43)
|
(51)
|
(56)
|
(55)
|
(33)
|
|
Net Income (Common) |
(10)
N/A
|
(43)
-344%
|
(51)
-19%
|
(56)
-9%
|
(55)
+1%
|
(33)
+41%
|
|
EPS (Diluted) |
-0.45
N/A
|
-1.99
-342%
|
-2.37
-19%
|
-1.81
+24%
|
-2.29
-27%
|
-0.74
+68%
|